Recently, the delegation of the "Seminar on Expanding International Markets for Developing Countries" – sponsored by China’s Ministry of Commerce and organized by the China Pilot Free Trade Zone Service Center – visited Bio-Sincerity. The 30 seminar participants are from government departments and enterprises of 6 countries, including Nigeria, South Africa, Mauritius, Nepal, Antigua and Barbuda, and The Gambia. They represent institutions such as the Nigeria Investment Promotion Commission, Nigeria Federal Ministry of Transportation, Ministry of Trade, Industry, Commerce and Consumer Affairs of Antigua and Barbuda, Gambia Investment Promotion Agency, and South African enterprise AYERISCENT. The participants gained an in-depth understanding of the development paths, international operation models, and pharmaceutical R&D service systems of China’s CXO enterprises, and jointly explored new global opportunities for cooperation in the pharmaceutical industry.

The delegation successively visited Bio-Sincerity’s exhibition hall, Impurity Research Center, and Formulation Laboratory, learning about the company’s core capabilities and global layout in fields such as improved new drugs, complex formulations, innovative drug R&D, and international registration. During the seminar and exchange, the Bio-Sincerity team shared practical experience in supporting partners’ global clinical trials, registrations, and market access.

"The R&D service model of Bio-Sincerity is highly worthy of learning. China’s professionalism and scale in the pharmaceutical R&D service field are impressive," said a seminar participant from Nigeria. He expressed the hope of having opportunities for deeper cooperation with Bio-Sincerity in aspects such as pharmaceutical technical support and project implementation in the future.

This seminar aims to promote exchanges and cooperation between China and various developing countries in enterprise international operations, opening a new window of opportunities for complementary advantages and common development between China and the participating countries. It not only deepened the participants’ understanding of China’s pharmaceutical CXO model but also injected new impetus into Bio-Sincerity’s efforts to deepen international exchanges and cooperation.